Indoco Remedies Limited · NSE:INDOCO
Indoco Remedies — Investor Presentation (June 2024)
34 slides from Indoco Remedies's investor presentation, Jun 10, 2024
Slide 1: Cover letter to stock exchanges
Date: June 10, 2024 To To The Listing Department The Listing Department National Stock Exchange of India Limited Bombay Stock Exchange Limited Exchange Plaza, Floor 25, P. J. Towers, Bandra – Kurla Complex Dalal Street, Bandra (East) Mumbai – 400 001 Mumbai – 400 051 Stock Code : 532612 Stock Code :
Slide 2: Indoco Remedies Limited Investor Presentation June 2024
Indoco Remedies Limited I N V E S T O R P R E S E N TAT I O N June 2024
Slide 3: Snapshot
S N A P S H OT 7 Decades 11 Manufacturing Facilities Employee of Presence in India 7 FDF Plants Strength >6000 4 API Plants R&D Facility (400+ scientists) Ranked 31st Development of complex Footprint as per IQVIA ophthalmics & injectables across 55+ countries (MAT – Apr’’24) NDDS & New Platform and
Slide 4: Company Overview
COMPANY OVERVIEW
Slide 5: Company Overview
C O M PA N Y O V E RV I E W • In 1945, our Founder, Late Mr. Govind Ramnath Kare founded ‘Indo- REVENUE (INR Mn) & EBITDA MARGINS (%) Continental Trading Company’, the principal business of which was to import pharmaceutical formulations from Europe and distribute them in the Western 17,620 16,381 I
Slide 6: Board of Directors
B O A R D O F D I R E C TO RS Mr. Suresh G. Kare - Chairman Ms. Aditi Panandikar - Managing Director Mr. Suresh G. Kare, Chairman of Indoco Remedies Ltd., has been at the helm of the Ms. Aditi Panandikar, the Managing Director at Indoco, is a third-generation entrepreneur with Company's affairs for
Slide 7: Key Management Personnel
KEY MANAGEMENT PERSONNEL Mr. Suresh G. Kare - Chairman Mr. Suresh G. Kare, Chairman of Indoco Remedies Ltd., has been at the helm of the Company's affairs for over 60 years. Under his able leadership, the Company has transformed into the fully integrated, research oriented pharma organization, that
Slide 8: Key Milestones
K E Y M I L E S TO N E S 2019 – till date • Indoco wins the "GOA BEST EMPLOYER BRAND AWARD 2009 - 2018 2023“ • New API manufacturing • Indoco wins the Lead 50 1999 - 2008 facility at Patalganga (next) supply chain award • New R&D centre at Rabale • Acquisition of Piramal's • Indoco completed 75 year
Slide 9: Geographical Footprint
G EO G R A P H I C A L F O OT P R I N T Baddi, Himachal Pradesh (2) Canada UK Netherlands Germany PolandBelarus France Ukraine Italy USA Spain Iraq Portugal Iran Lebanon Kuwait Jordan Bahrain Libya Algeria Egypt Qatar UAE Myanmar Taiwan Saudi Arabia Mauritania Mali Oman Senegal Niger Chad Yemen Thai
Slide 10: Manufacturing Plants - Formulations
M A N U FA C T U R I N G P L A N T S - F O R M U L AT I O N S Dosages manufactured Solid Orals (Tablets Coated / Uncoated) Dosages manufactured Liquid Orals Solid Orals (Tablets) Creams & Ointments Liquid Orals Capsules (Hard Gelatin) External Preparations (Creams & Ointments) Approved by UK-MHRA, T
Slide 11: Manufacturing Plants - Active Pharmaceutical Ingredients (API)
M A N U FA C T U R I N G P L A N T S – A C T I V E P H A R M A C U T I C A L I N G R E D I E N T S ( A P I ) API Plant I– Rabale API Plant II Kilolab - Rabale API Plant III - Patalganga API Plant - Warren, Aurangabad • Medium volume multipurpose APIs, • Small volume and high value APIs, • Medium and
Slide 12: State-of-the-Art R&D Center at Rabale, Navi Mumbai
S TAT E - O F - T H E - A R T R & D C E N T E R AT R A B A L E , N AV I M U M B A I R&D AS A PERCENTAGE OF SALES 1,200 972 9.9% 1,000 746 810 800 7.9% 597 4.9% 5.5% 600 5.0% 5.9% 400 4.9% 3.9% 200 1.9% - -0.1% FY21 FY22 FY23 FY24 R&D (INR Mn) as a percentage of sales Formulation R&D Focus: • Complex
Slide 13: Awards and Accolades
AWA R D S A N D A C C O L A D E S Indoco wins the ‘Goa Best Employer Lead 50 (NEXT) Supply Chain Award SAP ACE AWARD 2023 in the ‘Game ‘Three Star Export House’ Accreditation Brand Award 2023’ at the Vibrant Changer’ category GOA Inspiration Award 2023 Excellence in Pharma Supply Chain Excellence in
Slide 14: Business Overview
BUSINESS OVERVIEW
Slide 15: Business Segments
BUSINESS SEGMENTS DOMESTIC INTERNATIONAL ACTIVE PHARMA INGREDIENTS ALLIED SERVICES FORMULATION FORMULATION 48% 43% 7% 2% Branded Generics Regulated Markets - Active Pharma Ingredients (APIs) AnaCipher CRO Acute – 46% CRAMS for Generic Companies for captive consumption by BA / BE Studies. Sub-Chronic
Slide 16: Domestic Formulation Business
D O M E S T I C F O R M U L AT I O N B U S I N E S S • Indoco has a strong presence in the Indian formulations catering to both acute and chronic DOMESTIC FORMULATION SALES (INR Mn) therapies. 8,449 8,031 7,967 • The company is ranked 31st in (MAT Apr'24) and 22nd in Rx (MAT Apr'24) as per IQVIA. 6,
Slide 17: Domestic Formulation: Top Brands
D O M E S T I C F O R M U L AT I O N : TO P B R A N D S TOP BRANDS AND MARKET SHARE THERAPEUTIC SEGMENT & TOP BRANDS BLOOD RELATED, 1GYNAEC., 1 CARDIAC, 1 160 152 ANTI DIABETIC, 2 PAIN / ANALGESICS, STOMATOLOGICALS 3 , 19 140 51% 50% OTHERS, 7 120 111 VITAMINS/MINERA 103 LS/NUTRIENTS, 5 97 100 90 80
Slide 18: International Formulation Business
I N T E R N AT I O N A L F O R M U L AT I O N B U S I N E S S INTERNATIONAL FORMULATION SALES (INR Mn) • Indoco’s International Business is spread across both emerging and regulated markets, including United States of America, Europe, Australia, New Zealand. • It offers a complete solution including
Slide 19: Acquired 85% in Florida Pharmaceutical to Establish Front-End in the USA
A C Q U I R E D 8 5 % I N F LO R I D A P H A R M A C E U T I C A L TO E S TA B L I S H F R O N T - E N D I N T H E U S A • On Jun 6 2023, Indoco Remedies acquired 85% of equity stake of the US based Florida Pharmaceutical Products Holding Company, LLC (“FPP”) for $4 Million from Contract Pharmacal C
Slide 20: Active Pharmaceutical Ingredients (API)
ACTIVE PHARMACEUTICAL INGREDIENTS (API) • Indoco offers full range of services with respect to API supplies in Regulated markets. API SALES (INR Mn) • The distinct advantage of API business emanates from the backward integration of its 1,400 1,265 own ANDAs and Dossiers as well. 1,200 1,000 940 • In
Slide 21: Allied Services
ALLIED SERVICES Services Services • BA/BE studies Expertise, transparency, speed, and uncompromised quality are at the core of our • Healthy Male & Female Subjects operations, so we deliver value to our customers. Each of our verticals is operated by • Regulatory Services experts in their respective
Slide 22: Strategic Overview
STRATEGIC OVERVIEW
Slide 23: Strategies Undertaken
S T R AT E G I E S U N D E R TA K E N Significant Capex undertaken over the last 5 years to cater to future growth strategies for the next 2-3 years without any major incremental capex requirement 27% 5-year CAGR in International Revenues Acquired Florida Pharmaceutical in USA to have a direct prese
Slide 24: Future Growth Strategies
F U T U R E G R O W T H S T R AT E G I E S • Expand in Northern and Eastern regions • Exploring options for strategic in-licensing in chronic segment • Focusing on sales force effectiveness, new product launches, exploring new channels of distribution and increasing our potential • Focus on brand bu
Slide 25: Environment
ENVIRONMENT E • Encouraging SLS and Paraben free products - Sensodent K and Sensodent KF range of products • Indoco acquired a 26% stake each in Kanakal Wind Energy Private Limited and Jalansar Wind Energy Private Limited for setting up Solar Power plants at Akkalkot, Solapur District in Maharashtra
Slide 26: Social
SOCIAL S Sanitation Environment Education Health Infrastructure • Indoco is committed to its social responsibility and carries out its CSR activities under the banner of ‘SUMATI SANGOPAN’, reaching out to the unprivileged. • Indoco lends a helping hand to the underprivileged in society through the s
Slide 27: Governance
GOVERNANCE G • Indoco has adopted transparency, disclosure, accountability and Transparency ethics as its business practices. The management believes that these principles will enable it to achieve its long-term objectives and goals. • As part of its Corporate Governance philosophy, Indoco focuses o
Slide 28: Financial Overview
FINANCIAL OVERVIEW
Slide 29: Historical Standalone Financial Performance
H I S TO R I C A L S TA N D A LO N E F I N A N C I A L P E R F O R M A N C E PARTICULARS (INR Mn) FY21 FY22 FY 23 FY 24 Operational Revenue 12,174 15,027 16,381 17,620 Other Operating Income 229 370 286 289 Total Income from Operations 12,403 15,397 16,667 17,908 Operating Expenses 10,167 12,127 13,
Slide 30: Historical Standalone Balance Sheet
H I S TO R I C A L S TA N D A LO N E B A L A N C E S H E E T PARTICULARS (INR Mn) FY22 FY23 FY24 PARTICULARS (INR Mn) FY22 FY23 FY24 EQUITY 9,043 10,270 11,266 NON-CURRENT ASSETS 7,148 8,472 10,604 Equity Share Capital 184 184 184 a) Property, Plant and Equipment 5,205 5,785 6,197 Other Equity 8,859
Slide 31: Historical Financial Highlights
H I S TO R I C A L F I N A N C I A L H I G H L I G H T S OPERATIONAL REVENUE (INR Mn) EBITDA (INR Mn) & EBITDA PAT (INR Mn) & PAT MARGINS (%) 17,620 MARGINS (%) 16,381 1,545 15,027 1,414 3,270 12,174 2,849 2,580 1,166 2,236 924 21.8% 18.4% 17.4% 14.6% 10.3% 8.6% 6.6% 7.6% FY21 FY22 FY23 FY24 FY21 FY
Slide 32: Capital Market Information
C A P I TA L M A R K E T I N F O R M AT I O N 30% SHARE PRICE PERFORMANCE 25% 20% 15% 10% 5% 0% -5% -10% Apr-23 May-23 Jul-23 Aug-23 Sep-23 Nov-23 Dec-23 Feb-24 Mar-24 Sensex Indoco MARKET DATA AS ON 31st MARCH, 2024 SHAREHOLDING PATTERN AS ON 31ST MARCH, 2024 Face Value (INR) 2.0 DII FII CMP (INR)
Slide 33: Disclaimer
DISCLAIMER Indoco Remedies Limited Disclaimer: No representation or warranty, express or implied, is made as to, and no reliance should be placed on the fairness, accuracy, completeness or correctness of the information or opinions contained in this presentation. Such information and opinions are in
Slide 34: Thank You
THANK YOU